Current awareness in human psychopharmacology
2006; Wiley; Volume: 21; Issue: 5 Linguagem: Inglês
10.1002/hup.731
ISSN1099-1077
Tópico(s)Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
ResumoHuman Psychopharmacology: Clinical and ExperimentalVolume 21, Issue 5 p. 347-354 Current Awareness Current awareness in human psychopharmacology First published: 20 July 2006 https://doi.org/10.1002/hup.731AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs - General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. Current Awareness 1. Books, Reviews & Symposia Aguera LF, Rojo JE, Ros S, De la Gandara J, De Pedro JM. (2005). Antidepressant combinations: Epidemiological considerations. Acta Psychiatr Scand Suppl 112 7-10 Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT, Den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19 567-596 Barbui C, Lintas C, Percudani M. (2005). Head-to-head comparison of the costs of atypical antipsychotics - A systematic review. CNS Drugs 19 935-950 Becker PM. (2005). Pharmacologic and nonpharmacologic treatments of insomnia. Neurol Clin 23 1149-1163 Bourin M, Dhonnchadha BAN. (2005). 5-HT2 receptors and anxiety. Drug Dev Res 65 133-140 Bourre JM. (2005). Dietary ω-3 fatty acids and psychiatry: Mood, behaviour, stress, depression, dementia and aging. J Nutr Health Aging 9 31-38 Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, Scapicchio P, Senin U, Trabucchi M, Musicco M. (2005). Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging 22 1-26 Carrasco JL, Sandner C. (2005). Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: An overview. Int J Clin Pract 59 1428-1434 Chamorro Garcia L. (2005). Psychodrugs in the elderly (Spanish, English Abstract). Rev Clin Esp 205 513-517 Chenu F, Dailly E, Bourin M. (2005). 5-HT1B receptor: A target for antidepressant drugs?. Drug Dev Res 65 141-146 De la Gandara J, Rojo JE, Ros S, Aguera L, De Pedro JM. (2005). Neuropharmacological basis of combining antidepressants. Acta Psychiatr Scand Suppl 112 11-13 Dumortier G, Welniarz B, Sauvebois C, Medjdoub H, Friche H, Said N, Degrassat K. (2005). Prescription of psychotropic drugs in paediatry : Approved indications and therapeutic perspectives (French, English Abstract). Encephale 31 477-489 Fava GA, Ruini C, Rafanelli C. (2005). Sequential treatment of mood and anxiety disorders. J Clin Psychiatry 66 1392-1400 Gao KM, Gajwani P, Elhaj O, Calabrese JR. (2005). Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 66 1376-1385 Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. (2005). Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. Br Med J 331 1169 Hoogendijk WJG, Lieverse R, Beekman ATF. (2005). Suicide risk and antidepressants: Beyond the controversy. Drug Dev Res 65 179-184 Hughes JR, Stead LF, Lancaster T. (2005). Nortriptyline for smoking cessation: A review. Nicotine Tob Res 7 491-499 Isbister GK, Balit CR, Kilham HA. (2005). Antipsychotic poisoning in young children - A systematic review. Drug Saf 28 1029-1044 Kool S, Schoevers R, De Maat S, Van R, Molenaar P, Vink A, Dekker J. (2005). Efficacy of pharmacotherapy in depressed patients with and without personality disorders: A systematic review and meta-analysis. J Affect Disord 88 269-278 Lee MS. (2005). The pharmacogenetics of antidepressant treatments for depressive disorders. Drug Dev Res 65 170-178 Leo RJ, Baer D. (2005). Delirium associated with baclofen withdrawal: A review of common presentations and management strategies. Psychosomatics 46 503-507 Libby AM, Riggs PD. (2005). Integrated substance use and mental health treatment for adolescents: Aligning organizational and financial incentives. J Child Adolesc Psychopharmacol 15 826-834 Lindstrom E, Farde L, Eberhard J, Haverkamp W. (2005). QTc interval prolongation and antipsychotic drug treatments: Focus on sertindole. Int J Neuropsychopharmacol 8 615-629 Llorca PM, Brousse G, Schwan R. (2005). Escitalopram for treatment of major depressive disorder in adults (French, English Abstract). Encephale 31 490-501 Montgomery SA. (2005). Antidepressants and seizures: Emphasis on newer agents and clinical implications. Int J Clin Pract 59 1435-1440 Murdoch D, Keam SJ. (2005). Escitalopram - A review of its use in the management of major depressive disorder. Drugs 65 2379-2404 Penttila J, Scheinin H, Syvalahti E. (2005). Measurement of anticholinergic effects of psychotropic drugs in humans. Pharmacopsychiatry 38 187-193 Petrovic M, De Paepe P, Van Bortel L. (2005). Pharmacotherapy of depression in old age. Acta Clin Belg 60 150-156 Raber J. (2005). Histamine receptors as potential therapeutic targets to treat anxiety and depression. Drug Dev Res 65 126-132 Rojo JE, Ros S, Aguera L, De la Gandara J, De Pedro JM. (2005). Combined antidepressants: Clinical experience. Acta Psychiatr Scand Suppl 112 25-31 Ros S, Aguera L, De la Gandara J, Rojo JE, De Pedro JM. (2005). Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand Suppl 112 14-24 Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. (2005). Psychotropic drugs induced weight gain: A review of the literature concerning epidemiological data, mechanisms and management (French, English Abstract). Encephale 31 507-516 Schifano F, Deluca P, Agosti L, Martinotti G, Corkery JM, Alex B, Caterina B, Heikki B, Raffaella B, Anna C, Lucia DF, Dorte DR, Magi F, Susana F, Irene F, Claude G, Lisbet H, Lene SJ, Mauro L, Christopher L, Aino M, Teuvo P, Milena P, Salman R, Damien R, Angela RM, Francesco R, Norbert S, Holger S, Josep T, Marta T, Francesco Z. (2005). New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 (‘Blue Mystic’). J Psychopharmacol 19 675-679 Schreiber G, Avissar S. (2005). Mood disorders and their treatment: Alterations in the regulation of receptor-G protein coupling. Drug Dev Res 65 147-155 Stollberger C, Huber JO, Finsterer J. (2005). Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 20 243-251 Sun MK, Alkon DL. (2005). Protein kinase C substrate activators: Potential as novel antidepressants. Drug Dev Res 65 156-169 Tandon R, Fleischhacker WW. (2005). Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophr Res 79 145-155 Taylor MJ, Rudkin L, Hawton K. (2005). Strategies for managing antidepressant-induced sexual dysfunction: Systematic review of randomised controlled trials. J Affect Disord 88 241-254 Van den Bussche H. (2005). Problems and questions of pharmacological therapy of Alzheimer's disease with cholinesterase inhibitors (German, English Abstract). Z Gerontol Geriatr 38 i18-i20 Van Iersel MB, Zuidema SU, Koopmans RTCM, Verhey FRJ, Rikkert MGMO. (2005). Antipsychotics for behavioural and psychological problems in elderly people with dementia - A systematic review of adverse events. Drugs Aging 22 845-858 Vornik LA, Hirschfeld RMA. (2005). Bipolar disorder: Quality of life and the impact of atypical antipsychotics. Am J Managed Care 11 S275-S280 Walter MW. (2005). Monoamine reuptake inhibitors: Highlights of recent research developments. Drug Dev Res 65 97-118 Waxmonsky JG, Wilens TE. (2005). Pharmacotherapy of adolescent substance use disorders: A review of the literature. J Child Adolesc Psychopharmacol 15 810-825 Wilens TE, Monuteaux MC, Snyder LE, Moore H, Whitley J, Gignac M. (2005). The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: What does the literature tell us?. J Child Adolesc Psychopharmacol 15 787-798 Wilson JJ, Levin FR. (2005). Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol 15 751-763 Zimmermann M, Gardoni F, Di Luca M. (2005). Molecular rationale for the pharmacological treatment of Alzheimer's disease. Drugs Aging 22 27-37 2. General Heinze M, Andreae D, Grohmann R. (2005). Pharmacotherapy of personality disorders in German speaking countries: State and changes in the last decade. Pharmacopsychiatry 38 201-205 Matza LS, Rajagopalan KS, Thompson CL, De Lissovoy G. (2005). Misdiagnosed patients with bipolar disorder: Comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry 66 1432-1440 3. Psychotropic Drugs - General Andersen SW, Clemow DB, Corya SA. (2005). Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 66 1468-1476 Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. (2005). Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis. Ann Fam Med 3 449-456 Balon R. (2005). Sexual function and dysfunction during treatment with psychotropic medications. J Clin Psychiatry 66 1488-1489 Benazon NR, Mamdani MM, Coyne JC. (2005). Trends in the prescribing of antidepressants following acute myocardial infarction, 1993-2002. Psychosom Med 67 916-920 D'Arrigo C, Migliardi G, Santoro V, Morgante L, Muscatello MR, Ancione M, Spina E. (YR). Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res 52 497-501 Dannon PN, Lowengrub K, Musin E, Gonopolski Y, Kotler M. (2005). Sustained-release bupropion versus naltrexone in the treatment of pathological gambling a preliminary blind-rater study. J Clin Psychopharmacol 25 593-596 De la Gandara J, Aguera L, Rojo JE, Ros S, Pedro JM. (2005). Use of antidepressant combinations: Which, when and why? Results of a Spanish survey. Acta Psychiatr Scand Suppl 112 32-36 Jiang W, Davidson JRT. (2005). Antidepressant therapy in patients with ischemic heart disease. Am Heart J 150 871-881 Kieser M, Szegedi A. (2005). Predicting stable treatment response in patients with major depression treated with Hypericum extract WS 5570/5572. Pharmacopsychiatry 38 194-200 Kobak KA, Taylor LVH, Bystritsky A, Kohlenberg CJ, Greist JH, Tucker P, Warner G, Futterer R, Vapnik T. (2005). St John's wort versus placebo in obsessive-compulsive disorder: Results from a double-blind study. Int Clin Psychopharmacol 20 299-304 Kurdyak PA, Juurlink DN, Kopp A, Herrmann N, Mamdani MM. (2005). Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 25 561-564 Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, Foster VJ, Metz A, Rockett CB, Wightman DS. (2005). Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry 58 658-667 Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. (2005). Valerian-hops combination and diphenhydramine for treating insomnia: A randomized placebo-controlled clinical trial. Sleep 28 1465-1471 Nelson JC, Portera L, Leon AC. (2005). Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 66 1409-1414 Newton TF, Roache JD, De La Garza R, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) 182 426-435 Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. (2005). Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 25 527-532 Smit A, Tiemens BG, Ormel J, Kluiter H, Jenner JA, Van de Meer K, Van Os TWDP, Conradi HJ. (2005). Enhanced treatment for depression in primary care: First year results on compliance, self-efficacy, the use of antidepressants and contacts with the primary care physician. Prim Care Psychiatry 10 39-49 Sugahara H, Tokunaga S, Kondo T, Akamine M, Yoshimasu K, Fujisawa K, Fukudome K, Kanemitsu Y, Kubo C. (2005). Comparative adherence to antidepressant drugs in a non-psychiatric outpatient clinic setting in Japan. Prim Care Psychiatry 10 57-62 Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H. (2005). Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. J Clin Psychopharmacol 25 545-551 Van Brunt DL, Johnston JA, Ye WY, Pohl GM, Sun PJ, Sterling KL, Davis ME. (2005). Predictors of selecting atomoxetine therapy for children with attention deficit-hyperactivity disorder. Pharmacotherapy 25 1541-1549 Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. (2005). Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 22 59-67 Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M. (2005). An open-label study of duloxetine for the treatment of major depressive disorder - Comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol 25 552-560 Antidepressive Agents: 4. Tricyclics Veldhuijzen DS, Kenemans JL, Van Wijck AJM, Olivier B, Kalkman CJ, Volkerts ER. (2006). Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: Preliminary findings. Psychopharmacology (Berl) 183 462-470 6. Serotonergics Amsterdam JD, Shults J. (2005). Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 20 257-264 Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP. (2005). Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: Argos study. Depress Anxiety 22 68-76 Clark DB, Birmaher B, Axelson D, Monk K, Kalas C, Ehmann M, Bridge J, Wood DS, Muthen B, Brent D. (2005). Fluoxetine for the treatment of childhood anxiety disorders: Open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 44 1263-1270 Davidson JRI, Bose A, Wang Q. (2005). Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 66 1441-1446 Golding M, Kotlyar M, Carson SW, Hoyler S, Lazarus C, Davidson C, Guzzo J, Sontz E, Garbutt JC. (2005). Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnosis. Psychopharmacology (Berl) 182 321-326 Gothelf D, Rubinstein M, Shemesh E, Miller O, Farbstein I, Klein A, Weizman A, Apter A, Yaniv I. (2005). Pilot study: Fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer. J Am Acad Child Adolesc Psychiatry 44 1258-1262 Hesse C, Siedler H, Burhenne J, Riedel KD, Haefeli WE. (2005). Fluvoxamine affects sildenafil kinetics and dynamics. J Clin Psychopharmacol 25 589-592 Kamijima K, Kuboki T, Kumano H, Burt T, Cohen G, Arano I, Hamasaki T. (2005). A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 20 265-273 Kauffman RP, Castracane VD, White DL, Baldock SD, Owens R. (2005). Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 21 129-137 Keene MS, Eaddy MT, Nelson WW, Sarnes MW. (2005). Adherence to paroxetine CR compared with paroxetine IR in a medicare-eligible population with anxiety disorders. Am J Managed Care 11 S362-S369 Kim EJ, Yu BH. (2005). Increased cholesterol levels after paroxetine treatment in patients with panic disorder. J Clin Psychopharmacol 25 597-599 Kin NMKNY, Paris J, Schwartz G, Zweig-Frank H, Steiger H, Nair NPV. (2005). Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder. Psychopharmacology (Berl) 182 447-451 Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. (2005). Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 22 94-97 Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Gil FP, Leiberich PK, Rother N, Bachler E, Fartacek R, Kaplan P, Tritt K, Mitterlehner F, Anvar J, Rother WK, Loew TH, Egger C. (2005). Mirtazapine treatment of social phobia in women - A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 25 580-583 Pae CU, Kim TS, Lee KU, Kim JJ, Lee CU, Lee SJ, Lee C, Paik IH. (2005). Paroxetine-associated spontaneous sexual stimulation. Int Clin Psychopharmacol 20 339-341 Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M. (2005). The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol 8 523-528 Robinson SK, Viirre ES, Bailey KA, Gerke MA, Harris JP. (2005). Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med 67 981-988 Schule C, Baghai TC, Alajbegovic L, Schwarz M, Zwanzger P, Eser D, Schaaf L, Moller HJ, Rupprecht R. (2005). The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. Eur Arch Psychiatry Clin Neurosci 255 334-340 Seidman SN, Miyazaki M, Roose SP. (2005). Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men - Randomized placebo-controlled clinical trial. J Clin Psychopharmacol 25 584-588 Sheehan DV, Eaddy MT, Shah MB, Mauch RP. (2005). Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Managed Care 11 S354-S361 Van Oppen P, Van Balkom AJLM, De Haan E, Van Dyck R. (2005). Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: A 5-year follow-up. J Clin Psychiatry 66 1415-1422 Wilson SJ, Bailey JE, Rich AS, Nash J, Adrover M, Tournoux A, Nutt DJ. (2005). The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. J Psychopharmacol 19 609-613 Euthymic Agents: 7. Lithium Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Ganocy SJ, Findling RL. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 162 2152-2161 Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. (2005). Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. Am J Psychiatry 162 2162-2170 Tranquillizing Agents: 8. Major Acquaviva E, Gasquet I, Falissard B. (2005). Psychotropic combination in schizophrenia. Eur J Clin Pharmacol 61 855-861 Apiquian R, Fresan A, Ulloa RE, De la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, Nicolini H, Kapur S. (2005). Amoxapine as an atypical antipsychotic: A comparative study vs risperidone. Neuropsychopharmacology 30 2236-2244 Barak Y, Swartz M, Plopsky I. (2005). Assessing cardiovascular risks of olanzapine treatment: A 6-month study versus haloperidol in schizophrenia patients. Int Clin Psychopharmacol 20 315-317 Barbui C, Nose M, Bindman J, Schene A, Becker T, Mazzi MA, Kikkert M, Camara J, Born A, Tansella M. (2005). Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 25 521-526 Battaglia J, Houston JP, Ahl J, Meyers AL, Kaiser CJ. (2005). A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clin Ther 27 1612-1618 Biancosino B, Barbui C, Marmai L, Dona S, Grassi L. (2005). Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study. Int Clin Psychopharmacol 20 305-309 Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. (2005). Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 58 589-594 Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM. (2005). Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 79 281-288 Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. (2005). Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 182 494-498 Deshmukh A, Rosenbloom MJ, De Rosa E, Sullivan EV, Pfefferbaum A. (2005). Regional striatal volume abnormalities in schizophrenia: Effects of comorbidity for alcoholism, recency of alcoholic drinking, and antipsychotic medication type. Schizophr Res 79 189-200 Ehlis AC, Zielasek J, Herrmann MJ, Ringel T, Jacob C, Fallgatter AJ. (2005). Beneficial effect of atypical antipsychotics on prefrontal brain function in acute psychotic disorders. Eur Arch Psychiatry Clin Neurosci 255 299-307 Griffiths C, Flanagan RJ. (2005). Fatal poisoning with antipsychotic drugs, England and Wales 1993-2002. J Psychopharmacol 19 667-674 Hamann J, Kolbe G, Cohen R, Leucht S, Kissling W. (2005). How do psychiatrists choose among different antipsychotics?. Eur J Clin Pharmacol 61 851-854 Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY. (2005). Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 78 520-528 Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. (2005). Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30 2283-2289 Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J, Yuen H, Schacht M, Edwards J, Naber D, McGorry PD. (2005). Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: Results of an open retrospective medical record study. Pharmacopsychiatry 38 206-213 LeBlanc JC, Binder CE, Armenteros JL, Aman MG, Wang JS, Hew H, Kusumakar V. (2005). Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: Analysis of two placebo-controlled randomized trials. Int Clin Psychopharmacol 20 275-283 Lee KU, Won WY, Lee HK, Kweon YS, Lee CT, Pae CU, Bahk WM. (2005). Amisulpride versus quetiapine for the treatment of delirium: A randomized, open prospective study. Int Clin Psychopharmacol 20 311-314 Liu GG, Sun SX, Christensen DB, Zhao ZY. (2005). Choice of atypical antipsychotic therapy for patients with schizophrenia: An analysis of a Medicaid population. Curr Ther Res 66 463-474 Mackin P, Young AH. (2005). QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: A preliminary study. J Clin Psychiatry 66 1386-1391 Marchiaro L, Rocca P, LeNoci F, Longo P, Montemagni C, Rigazzi C, Bogetto F. (2005). Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia. J Clin Psychiatry 66 1423-1431 Pae CU, Ghaemi SN, Kim TS, Kim JJ, Lee SJ, Lee CU, Lee C, Paik IH. (2005). Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: A preliminary trial. Int Clin Psychopharmacol 20 327-330 Perquin LNM. (2005). Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol 20 335-338 Sernyak MJ, Gulanski B, Rosenheck R. (2005). Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 66 1463-1467 Sethuraman G, Taylor CC, Enerson M, Dunayevich E. (2005). A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res 79 337-340 Stathis S, Martin G, McKenna JG. (2005). A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. J Clin Psychopharmacol 25 539-544 Szulc A, Galinska B, Tarasow E, Dzienisz W, Kubas B, Konarzewska B, Walecki J, Alathiaki AS, Czernikiewicz A. (2005). The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS) study. Pharmacopsychiatry 38 214-219 Toda H, Kusumi I, Sasaki Y, Ito K, Koyama T. (2005). Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium. Int Clin Psychopharmacol 20 331-333 Verhey FRJ, Verkaaik M, Lousbert R. (2006). Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: Results of a randomized controlled double-blind trial. Dement Geriatr Cogn Disord 21 1-8 Volavka J, Czobor P, Citrome L, McQuade RD, Carson WH, Kostic D, Hardy S, Marcus R. (YR). Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: Data from 5 double-blind studies. J Clin Psychiatry 66 1362-1366 Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 2335-2341 Yang CH, Tsai SJ, Hwang JP. (2005). The efficacy and safety of quetiapine for treatment of geriatric psychosis. J Psychopharmacol 19 661-666 Ziegenbein M, Kropp S, Kuenzel HE. (2005). Combination of clozapine and ziprasidone in treatment-resistant schizophrenia - An open clinical study. Clin Neuropharmacol 28 220-224 9. Minor & Hypnotics Hermos JA, Young MM, Lawler EV, Stedman MR, Gagnon DR, Fiore LD. (2005). Characterizations of long-term anxiolytic benzodiazepine - Prescriptions in veteran patients. J Clin Psychopharmacol 25 600-604 Jackson A, Stephens D, Duka T. (2005). Gender differences in response to lorazepam in a human drug discrimination study. J Psychopharmacol 19 614-619 Pomara N, Willoughby LM, Ritchie JC, Sidtis JJ, Greenblatt DJ, Nemeroff CB. (2005). Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. Psychopharmacology (Berl) 182 414-419 Tcheremissine OV, Lane SD, Lieving LM, Rhoades HM, Nouvion S, Cherek DR. (2005). Individual differences in aggressive responding to intravenous flumazenil administration in adult mate parolees. J Psychopharmacol 19 640-646 10. Analeptic Agents Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L. (2005). Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116 e777-e784 Carpentier PJ, De Jong CAJ, Dijkstra BAG, Verbrugge CAG, Krabbe PFM. (2005). A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 100 1868-1874 Dartigues JF, Douet C, Rey M, Sencey M, Pigeon M, Sardin F, Maugendre P, Crochet B. (YR). Prescription of cholinesterase inhibitors in Alzheimer's disease in France in 2000-2001: An assessment of compliance with national guidelines for diagnosis and follow-up (French, English Abstract). Rev Neurol (Paris) 161 957-962 Fredericks EM, Kollins SH. (2005). A pilot study of methylphenidate preference assessment in children diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15 729-741 James JE, Rogers PJ. (2005). Effects of caffeine on performance and mood: Withdrawal reversal is the most plausible explanation. Psychopharmacology (Berl) 182 1-8 Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. (2005). Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: A population-based, birth cohort study. J Child Adolesc Psychopharmacol 15 764-776 Kircher TTJ, Erb M, Grodd W, Leube DT. (2005). Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease - Preliminary findings from a pharmaco-fMRI study. A
Referência(s)